Esperion Therapeutics Inc. Revenue 2018–2025
Esperion Therapeutics Inc. annual/quarterly revenue history and growth rate from 2018 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Esperion Therapeutics Inc. revenue for the quarter ending March 31, 2026 was 80.1 M, a 23.25% increase year-over-year.
- Esperion Therapeutics Inc. revenue for the twelve months ending March 31, 2026 was 314.8 M, a 5.93% increase year-over-year.
- Esperion Therapeutics Inc. annual revenue for 2025 was 403.1 M, a 21.31% increase from 2024.
- Esperion Therapeutics Inc. annual revenue for 2024 was 332.3 M, a 185.66% increase from 2023.
- Esperion Therapeutics Inc. annual revenue for 2023 was 116.3 M, a 54.14% increase from 2022.
- Esperion Therapeutics Inc. annual revenue for 2022 was 75.5 M.
Esperion Therapeutics Inc. (ESPR) — Frequently Asked Questions
Esperion Therapeutics Inc. (ESPR) is a publicly traded US company. It has a market capitalization of $653M. In fiscal 2025 it reported revenue of $403M and net income of -$23M. Explore ESPR's stock price, financial statements, earnings history, margins and key ratios below.
What is Esperion Therapeutics Inc.'s market cap?
Esperion Therapeutics Inc. (ESPR) has a market capitalization of $653M.
What is the ESPR stock price?
ESPR trades at $3.14.
How much revenue does Esperion Therapeutics Inc. make?
Esperion Therapeutics Inc. reported revenue of $403M in fiscal 2025.
Is ESPR profitable?
In fiscal 2025, Esperion Therapeutics Inc. reported net income of -$23M.